OpGen Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.21
- Today's High:
- $0.225
- Open Price:
- $0.2121
- 52W Low:
- $0.165
- 52W High:
- $9.2
- Prev. Close:
- $0.208
- Volume:
- 441814
Company Statistics
- Market Cap.:
- $1.85 million
- Book Value:
- 0.985
- Revenue TTM:
- $2.82 million
- Operating Margin TTM:
- -756.31%
- Gross Profit TTM:
- $-8990133
- Profit Margin:
- 0%
- Return on Assets TTM:
- -37.42%
- Return on Equity TTM:
- -211.58%
Company Profile
OpGen Inc had its IPO on 2015-05-05 under the ticker symbol OPGN.
The company operates in the Healthcare sector and Medical Devices industry. OpGen Inc has a staff strength of 85 employees.
Stock update
Shares of OpGen Inc opened at $0.21 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.21 - $0.23, and closed at $0.22.
This is a +5.77% increase from the previous day's closing price.
A total volume of 441,814 shares were traded at the close of the day’s session.
In the last one week, shares of OpGen Inc have increased by +10.55%.
OpGen Inc's Key Ratios
OpGen Inc has a market cap of $1.85 million, indicating a price to book ratio of 0.4623 and a price to sales ratio of 2.4715.
In the last 12-months OpGen Inc’s revenue was $2.82 million with a gross profit of $-8990133 and an EBITDA of $-19941016. The EBITDA ratio measures OpGen Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, OpGen Inc’s operating margin was -756.31% while its return on assets stood at -37.42% with a return of equity of -211.58%.
In Q2, OpGen Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 23.9%.
OpGen Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-11.91 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into OpGen Inc’s profitability.
OpGen Inc stock is trading at a EV to sales ratio of 3.505 and a EV to EBITDA ratio of -0.4179. Its price to sales ratio in the trailing 12-months stood at 2.4715.
OpGen Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $22.43 million
- Total Liabilities
- $12.42 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $367315
- Dividend Payout Ratio
- 0%
OpGen Inc ended 2024 with $22.43 million in total assets and $0 in total liabilities. Its intangible assets were valued at $22.43 million while shareholder equity stood at $6.86 million.
OpGen Inc ended 2024 with $0 in deferred long-term liabilities, $12.42 million in other current liabilities, 69677.00 in common stock, $-284388698.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.24 million and cash and short-term investments were $3.24 million. The company’s total short-term debt was $9,710,715 while long-term debt stood at $0.
OpGen Inc’s total current assets stands at $7.23 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $619575.00 compared to accounts payable of $195253.00 and inventory worth $1.74 million.
In 2024, OpGen Inc's operating cash flow was $0 while its capital expenditure stood at $367315.
Comparatively, OpGen Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.22
- 52-Week High
- $9.2
- 52-Week Low
- $0.165
- Analyst Target Price
- $3
OpGen Inc stock is currently trading at $0.22 per share. It touched a 52-week high of $9.2 and a 52-week low of $9.2. Analysts tracking the stock have a 12-month average target price of $3.
Its 50-day moving average was $0.46 and 200-day moving average was $1.27 The short ratio stood at 0.73 indicating a short percent outstanding of 0%.
Around 78% of the company’s stock are held by insiders while 322.1% are held by institutions.
Frequently Asked Questions About OpGen Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company’s products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.